BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 32787587)

  • 1. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Kamal Y; Schmit SL; Frost HR; Amos CI
    Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.
    Subtil B; Cambi A; Tauriello DVF; de Vries IJM
    Front Immunol; 2021; 12():724883. PubMed ID: 34691029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Modeling the Immune Microenvironment of Colorectal Cancer.
    Yoon PS; Del Piccolo N; Shirure VS; Peng Y; Kirane A; Canter RJ; Fields RC; George SC; Gholami S
    Front Immunol; 2020; 11():614300. PubMed ID: 33643296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Expanding Role for Immunotherapy in Colorectal Cancer.
    Bever KM; Le DT
    J Natl Compr Canc Netw; 2017 Mar; 15(3):401-410. PubMed ID: 28275038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.
    Nenkov M; Ma Y; Gaßler N; Chen Y
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer.
    Xiong Y; Wang Y; Tiruthani K
    Nanomedicine; 2019 Oct; 21():102034. PubMed ID: 31207314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Tumor Microenvironment-Activated Bio-Decomposable and Metabolizable Cu
    Chang M; Hou Z; Jin D; Zhou J; Wang M; Wang M; Shu M; Ding B; Li C; Lin J
    Adv Mater; 2020 Oct; 32(43):e2004647. PubMed ID: 32945002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
    Guo L; Wang C; Qiu X; Pu X; Chang P
    Front Immunol; 2020; 11():1052. PubMed ID: 32547556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.
    Zheng X; Ma Y; Bai Y; Huang T; Lv X; Deng J; Wang Z; Lian W; Tong Y; Zhang X; Yue M; Zhang Y; Li L; Peng M
    Front Immunol; 2022; 13():984480. PubMed ID: 36389763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer.
    Maoz A; Dennis M; Greenson JK
    Front Immunol; 2019; 10():1884. PubMed ID: 31507584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer.
    Nussbaum YI; Manjunath Y; Suvilesh KN; Warren WC; Shyu CR; Kaifi JT; Ciorba MA; Mitchem JB
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for colorectal cancer: where are we heading?
    Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
    Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
    Aristin Revilla S; Kranenburg O; Coffer PJ
    Front Immunol; 2022; 13():903564. PubMed ID: 35874729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.